Press Releases

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Aug 22, 2022
2022
Press Release Regulatory

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2022

Regulatory
Read more
Aug 12, 2022
2022
Press Release Non-regulatory

Elicera Therapeutics announces participation in several industry and partnering conferences

Read more
Jun 2, 2022
2022
Press Release Regulatory

Elicera Therapeutics receives 2.5 million Euros in EU funding to fully finance a clinical phase I/II-trial with its CAR T-cell therapy, ELC-301

Regulatory
Read more
Apr 27, 2022
2022
Press Release Non-regulatory

Elicera Therapeutics successfully concludes preclinical proof-of-concept studies for oncolytic virus ELC-201 confirming the proposed mode-of-action

Read more
Apr 26, 2022
2022
Press Release Regulatory

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2022

Regulatory
Read more
Apr 4, 2022
2022
Press Release Regulatory

Elicera Therapeutics publishes scientific article in Nature Biomedical Engineering on the iTANK-platform and data indicating its universal compatibility with other CAR T-cell therapies

Regulatory
Read more
Feb 24, 2022
2022
Press Release Non-regulatory

Elicera Therapeutics’ Chief Scientific Officer, Professor Magnus Essand, to present at SWECARNET’s Educational Day 2022

Read more
Feb 4, 2022
2022
Press Release Regulatory

Elicera Therapeutics publishes annual report for 2021

Regulatory
Read more
Jan 25, 2022
2022
Press Release Regulatory

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 December 2021

Regulatory
Read more
Jan 18, 2022
2022
Press Release Non-regulatory

Elicera Therapeutics secures 5 million SEK in funding from Vinnova to develop an automated CAR T-cell manufacturing process

Read more
Jan 14, 2022
2022
Press Release Regulatory

The Nomination Committee for Elicera Therapeutics proposes re-election of Board

Regulatory
Read more
Jan 5, 2022
2022
Press Release Non-regulatory

Elicera Therapeutics strengthens IP protection for ELC-100 through acquisition of patent from Immunicum

Read more
Dec 15, 2021
2021
Press Release Non-regulatory

Elicera Therapeutics enters into agreement with Baylor College of Medicine for contract manufacturing of next generation oncolytic virus, ELC-201

Read more
Nov 18, 2021
2021
Press Release Regulatory

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 September 2021

Regulatory
Read more
Nov 9, 2021
2021
Press Release Non-regulatory

Elicera Therapeutics enters agreement with BioNTech for contract manufacturing of viral vectors for CAR T-cell therapy

Read more
Nov 4, 2021
2021
Press Release Regulatory

Nomination Committee for Elicera Therapeutics appointed

Regulatory
Read more
Oct 22, 2021
2021
Press Release Non-regulatory

Elicera Therapeutics appoints professor Gunilla Enblad, Key Opinion Leader within the fields of CAR T-cells and B-cell lymphoma, as scientific advisor

Read more
Oct 20, 2021
2021
Press Release Regulatory

Elicera Therapeutics presents preclinical proof-of-concept data for its iTANK-platform at the European Society of Cell & Gene Therapy Congress

Regulatory
Read more
Oct 5, 2021
2021
Press Release Non-regulatory

Elicera Therapeutics announces participation in several industry and investor meetings in October and November

Read more
Sep 13, 2021
2021
Press Release Non-regulatory

Elicera Therapeutics will present the iTANK platform orally at ESGCT Collaborative Virtual Congress and PEGS Europe

Read more

Sign up for Press Releases

By filling out the form you are approving that Elicera stores your information. Read more about our integrity policy here.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
By continuing to browse this website you agree to cookies being stored on your device in order to improve the experience and analyze how it is being used. Read more in our Integrity policy.